Brachytherapy
Volume 6, Issue 1 , Pages 16-25 , January 2007

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

  • Rodney J. Ellis

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH
    • Department of Radiology, Northeastern Ohio Universities College of Medicine, Rootstown, OH
    • Division of Urology, MetroHealth Medical Center, University Hospitals of Cleveland, Cleveland, OH
    • Corresponding Author InformationCorresponding author. Stark Radiation Oncology, 2600 Sixth Street, SW, PO Box 80468, Canton, OH 44710, USA. Tel.: +1-330-363-6201; fax: +1-330-454-9397.
    • ,
  • Hang Zhou

      Affiliations

    • Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH
    • Department of Epidemiology and Biostatistics, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Edward Y. Kim

      Affiliations

    • Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Pingfu Fu

      Affiliations

    • Department of Epidemiology and Biostatistics, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Deborah A. Kaminsky

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • ,
  • Bruce Sodee

      Affiliations

    • Department of Radiology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Valdir Colussi

      Affiliations

    • Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Waseet Z. Vance

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • ,
  • John P. Spirnak

      Affiliations

    • Division of Urology, MetroHealth Medical Center, University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Carolyn Kim

      Affiliations

    • Department of Radiation Oncology, Aultman Hospital, Canton, OH
    • ,
  • Martin I. Resnick

      Affiliations

    • Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH

Received 1 August 2006 ,Revised 1 November 2006 ,Accepted 3 November 2006.

References 

  1. Cancer facts and figures. American Cancer Society, Atlanta, GA; 2005;17–19
  2. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys. 2003;57:944–952
  3. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  4. Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352–1359
  5. Fletcher SG, Theodorescu D. Surgery or radiation: What is the optimal management for locally advanced prostate cancer?. Can J Urol. 2005;12(Suppl. 1):58–61discussion 101–102
  6. Quaranta BP, Marks LB, Anscher MS. Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Williston Park). 2004;18:1289–1302discussion 302–304, 309
  7. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43:316–381
  8. D'Souza WD, Thames HD, Kuban DA. Dose-volume conundrum for response of prostate cancer to brachytherapy: Summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys. 2004;58:1540–1548
  9. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  10. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  11. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  12. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med. 2004;45:1509–1518
  13. Zaider M, Zelefsky MJ, Lee EK, et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2000;47:1085–1096
  14. Ellis RJ, Sodee DB, Spirnak JP, et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:683–687
  15. Ellis RJ, Vertocnik A, Sodee B, et al. Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Brachytherapy. 2003;2:215–222
  16. Wright GL, Haley C, Beckett M, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28
  17. Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–6362
  18. Ellis RJ, Kim EY, Conant R, et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys. 2001;49:1281–1286
  19. Sodee DB, Ellis RJ, Samuels MA, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: Semiquantitative correlation with prostatic biopsy results. Prostate. 1998;37:140–148
  20. Ellis RJ, Vertocnik A, Kim E, et al. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2003;57:362–370
  21. Ellis RJ, Kim E, Foor R. Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma. Expert Rev Mol Diagn. 2004;4:435–441
  22. Ellis RJ. Radioimmuno-guided prostate brachytherapy. In:  Dicker A,  Merrick G,  Gomella L editor. Basic and advanced prostate brachytherapy. London: Martin Dunitz Publishing; 2005;p. 221–232
  23. Burke HB, Henson DE. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer. 1993;72:3131–3135
  24. Saw CB, Meigooni AS, Nath R. Review of AAPM Task Group No. 43 recommendations on interstitial brachytherapy sources dosimetry. American Association of Physicists in medicine. Med Dosim. 1998;23:259–263
  25. Beyer D, Nath R, Butler W, et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103) palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2000;47:273–275
  26. Williamson JF, Coursey BM, DeWerd LA, et al. Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 interstitial sources: Dosimetry and calibration changes: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on low-energy seed dosimetry. Med Phys. 1999;26:570–573
  27. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  28. Kuban D, Thames H, Levy L, et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all?. Int J Radiat Oncol Biol Phys. 2005;61:409–414
  29. Yock TI, Zietman AL, Shipley WU, et al. Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54:420–426
  30. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  31. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  32. Cox DR. Regression models and life-tables. J Royal Stat Soc B. 1972;34:187–220
  33. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;63(S1):S33–S34
  34. Fitch DL, McGrath S, Martinez AA, et al. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Int J Radiat Oncol Biol Phys. 2006;66:1430–1439
  35. Beyer DC, McKeough T, Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:1299–1305
  36. Ash D, Al-Qaisieh B, Bottomley D, et al. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localized prostate cancer. Radiother Oncol. 2005;75:303–306
  37. Andrews J, Roach M. Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer. Oncology (Williston Park). 2005;19:29–36
  38. Beyer DC, Thomas T, Hilbe J, et al. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy. 2003;2:77–84
  39. Ellis RJ, Zhou H, Fu P, et al. SPECT/CT capromab pendetide independently predicts bDFS in long term outcome study. [Abstract] J Urol. 2006;175(4):S:532
  40. Sodee DB, Nelson AD, Faulhaber PF, et al. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005;3:230–238
  41. Seo Y, Franc BL, Hawkins RA, et al. Progress in SPECT/CT imaging of prostate cancer. Technol Cancer Res Treat. 2006;5:329–336
  42. In:  Israel O,  Goldsmith SJ editor. Hybrid SPECT/CT imaging in clinical practice. Informa Healthcare Publishing; 2006;

 This article includes uses of a US Food and Drug Admistration approved agent (ProstaScint) outside its current labeled indications. The agent's package insert should be consulted for complete prescribing information.Financial Disclosure: Dr. Ellis has an unrestricted research grant and speakers bureau funding from the Cytogen Corporation, Princeton, NJ.

PII: S1538-4721(06)00299-6

doi: 10.1016/j.brachy.2006.11.002

Brachytherapy
Volume 6, Issue 1 , Pages 16-25 , January 2007

Article Tools

* Image Usage & Resolution